Dermatology · Corticosteroid
The FDA's approval of Rising's hydrocortisone ANDA218298 introduces a new competitor into the dermatology corticosteroid market. This development could disrupt pricing and market share dynamics, necessitating strategic adjustments from existing players.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/23/2026, 12:31:21 PM
Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Rising's hydrocortisone ANDA218298 introduces a new competitor into the dermatology corticosteroid market. This development could disrupt pricing and market share dynamics, necessitating strategic adjustments from existing players. Regulatory context from FDA (FDA AP — HYDROCORTISONE (ORIG)) supports the near-term read. Assessment grounded in 15 ranked evidence items (6 high-relevance).
Portfolio teams should assess the impact of Rising's entry on market share and pricing strategies for hydrocortisone products. The strongest clinical anchor is Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. In Dermatology · Corticosteroid, 4 regulatory and 3 competitive items passed relevance filtering for existing competitors.
The most relevant competitive pressure comes from FDA Grants Priority Review for ZAYNICH NDA Submission by Wockhardt Bio AG (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA Grants Approval for Tofacitinib Citrate (ANDA217298). This approval allows Rising to enter the hydrocortisone market, potentially increasing competition among existing players.
Regulatory risk is concentrated around FDA AP — HYDROCORTISONE (ORIG) (FDA). Regulatory pathway relevance (nda). The approval signifies compliance with FDA standards, but does not introduce significant regulatory changes for existing products in the market.
FDA AP — HYDROCORTISONE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceAdvancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceRare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceFDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceLong-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceVibratory Anesthesia on Pain Following Corticosteroid Injections
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFactors Influencing Fertility or Pregnancy Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceINcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceReal-time Neuromuscular Control of Exoskeletons
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceIntestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Grants Priority Review for ZAYNICH NDA Submission by Wockhardt Bio AG
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA Grants Approval for Tofacitinib Citrate (ANDA217298)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Tofacitinib Citrate ANDA220137
Humanexa Signalsmedium relevance
Moderate corpus alignment
The role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Rising's hydrocortisone ANDA218298 introduces a new competitor into the dermatology corticosteroid market. This development could disrupt pricing and market share dynamics, necessitating strategic adjustments from existing players.
Rising's entry may lead to increased competition, potentially impacting revenue and market share for established hydrocortisone products. Companies will need to reassess their pricing strategies to maintain competitiveness.
The approval signifies compliance with FDA standards, but does not introduce significant regulatory changes for existing products in the market.
Monitor market response and sales performance of Rising's hydrocortisone product post-launch.
Track for follow-up milestones; no immediate action required.